Navigation Links
Genmab Reaches Milestones in Ofatumumab Collaboration
Date:1/21/2008

Summary: Genmab has Achieved Two Development Milestones in its Ofatumumab

Collaboration With GlaxoSmithKline.

COPENHAGEN, January 21 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has reached the second and third development milestones for ofatumumab (HuMax-CD20(R)) under the terms of its collaboration with GlaxoSmithKline (GSK).

The second milestone payment of the collaboration of DKK 87.2 million was triggered by treatment of the first patient in the Phase II study of ofatumumab in Diffuse Large B-Cell Lymphoma (DLBCL), which occurred in 2007. The third milestone payment of DKK 87.2 million was triggered by the first patient receiving treatment in the Phase III rheumatoid arthritis (RA) program, which occurred in 2008.

Genmab achieved the first development milestone payment of DKK 116.3 million under the GSK collaboration in June, triggered by positive efficacy results in the Phase II RA study.

Ofatumumab is an investigational, fully human, next generation monoclonal antibody that targets a distinct small loop epitope on the CD20 receptor on the surface of B-cells. This epitope is different to the other anti-CD20 antibodies currently available or in development. Ofatumumab is being developed under a co-development and commercialization agreement between Genmab and GlaxoSmithKline.

"Genmab and GSK have worked hard to expand development with ofatumumab since our collaboration began in December 2006," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "The successful initiation of the ofatumumab RA and DLBCL programs are a testament to the cooperative spirit of our companies."

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using unique, cutting-edge antibody technology, Genmab's world class discovery and development teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders.

As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit http://www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R); HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-CD32b(TM) and UniBody(R) are all trademarks of Genmab A/S.

Contact:

Helle Husted

Sr. Director

Investor Relations

T: +45-33-44-77-30

M: +45-25-27-47-13

E: hth@genmab.com


'/>"/>
SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genmab Announces HuMax-CD32b Pre-Clinical Program
2. Roche Files IND for Second Genmab Antibody
3. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
4. Genmab Announces Details of Planned Ofatumumab Phase II Study in Multiple Sclerosis
5. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
6. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
7. Genmab Announces Results for the First Nine Months of 2007
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
10. Genmab A/S - Company Announcement
11. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... ... technology at the Spring 2016 Marijuana Business Conference and Expo. Shimadzu’s high-performance instruments ... heavy metals, and more. Expo attendees can stop by booth 1021 to learn ...
(Date:4/27/2016)... ... April 27, 2016 , ... ... mobile devices with fingerprint recognition for secure access, voice recognition for hands-free communication, ... ways consumers are interacting with biometrics technology today. But if they asked ...
(Date:4/27/2016)... SILVER SPRING, Md. and RESEARCH ... -- United Therapeutics Corporation (NASDAQ: UTHR ) announced ... Co-Chief Executive Officer, of United Therapeutics will provide an ... Deutsche Bank 41 st Annual Health Care Conference. ... May 5, 2016, at 10:00 a.m. Eastern Time, and ...
(Date:4/27/2016)... , ... April 27, 2016 , ... ... Jon Clark has joined the company as an Expert Consultant. Mr. Clark ... industry collaborations and managing the development of small molecule monographs based on analytical ...
Breaking Biology Technology:
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
(Date:3/21/2016)... , March 22, 2016 ... with passcodes for superior security   ... leading provider of secure digital communications services, today announced ... technology and offer enterprise customers, particularly those in the ... recognition and voice authentication within a mobile app, alongside, ...
Breaking Biology News(10 mins):